» Articles » PMID: 17469937

Stress and Drug-cue-induced Craving in Opioid-dependent Individuals in Naltrexone Treatment

Overview
Specialty Pharmacology
Date 2007 May 2
PMID 17469937
Citations 76
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Naltrexone is a nonaddictive medication that blocks the euphoric effects of opioids. However, naltrexone treatment is associated with high rates of noncompliance and opioid relapse, possibly because it does not reduce stress and protracted withdrawal symptoms during early recovery. Prior clinical and preclinical research has indicated that both stress and drug-cue-related arousal response is associated with craving and vulnerability to relapse in a range of drug-using populations.

Aims: To examine opioid craving and the subjective and cardiovascular response to stress and drug cues in naltrexone-treated opioid abusers.

Method: Eleven men and three women engaged in naltrexone treatment for opioid dependence. They were exposed to personalized stress, drug-cue, and neutral-relaxing imagery in a single laboratory session. Subjective (craving, emotion) and cardiovascular (heart rate, systolic blood pressure, and diastolic blood pressure) measures were assessed.

Results: Stress and drug-cue-related imagery significantly increased opioid craving, anxiety, and negative emotions and significantly decreased positive emotions compared to neutral imagery. Selective emotional responses were greater in the stress condition than in the drug-cue condition. Only stress-related imagery was associated with an increased cardiovascular response.

Conclusions: Naltrexone-treated opioid abusers demonstrate vulnerability to stress and drug-cue-induced craving and arousal responses that may contribute to the high rates of noncompliance and relapse among opioid-dependent individuals undergoing naltrexone treatment. Pharmacological and behavioral interventions that specifically target the negative affectivity that co-occurs with drug-cue and stress-induced craving could be of benefit in improving naltrexone treatment outcomes in opioid dependence.

Citing Articles

Left ventromedial prefrontal cortex inhibitory rTMS as an anti-stress intervention in opioid use disorder: Trial design.

Moses T, Lenz D, Lundahl L, Mischel N, Rabinak C, Greenwald M Contemp Clin Trials Commun. 2025; 43():101414.

PMID: 39802663 PMC: 11719330. DOI: 10.1016/j.conctc.2024.101414.


Oral fentanyl consumption and withdrawal impairs fear extinction learning and enhances basolateral amygdala principal neuron excitatory-inhibitory balance in male and female mice.

Downs A, Kmiec G, McElligott Z Addict Neurosci. 2025; 13.

PMID: 39742087 PMC: 11687336. DOI: 10.1016/j.addicn.2024.100182.


Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior.

Illenberger J, Flores-Ramirez F, Pascasio G, Franco M, Mendonsa B, Martin-Fardon R J Psychopharmacol. 2024; 38(7):647-660.

PMID: 38888086 PMC: 11407285. DOI: 10.1177/02698811241260989.


Effects of neuromodulation on cognitive and emotional responses to psychosocial stressors in healthy humans.

Moses T, Gray E, Mischel N, Greenwald M Neurobiol Stress. 2023; 22:100515.

PMID: 36691646 PMC: 9860364. DOI: 10.1016/j.ynstr.2023.100515.


What Prevention and Treatment of Substance Dependence Can Tell Us About Addressing Violent Extremism.

Brown R, Ramchand R, Helmus T Rand Health Q. 2022; 9(4):15.

PMID: 36238006 PMC: 9519093.


References
1.
Aston-Jones G, Harris G . Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology. 2004; 47 Suppl 1:167-79. DOI: 10.1016/j.neuropharm.2004.06.020. View

2.
Kabat-Zinn J, Massion A, Kristeller J, Peterson L, Fletcher K, Pbert L . Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. Am J Psychiatry. 1992; 149(7):936-43. DOI: 10.1176/ajp.149.7.936. View

3.
Sorge R, Rajabi H, Stewart J . Rats maintained chronically on buprenorphine show reduced heroin and cocaine seeking in tests of extinction and drug-induced reinstatement. Neuropsychopharmacology. 2005; 30(9):1681-92. DOI: 10.1038/sj.npp.1300712. View

4.
McCubbin J, Bruehl S, Wilson J, Sherman J, Norton J, Colclough G . Endogenous opioids inhibit ambulatory blood pressure during naturally occurring stress. Psychosom Med. 1998; 60(2):227-31. DOI: 10.1097/00006842-199803000-00020. View

5.
Le A, Harding S, Juzytsch W, Watchus J, Shalev U, Shaham Y . The role of corticotrophin-releasing factor in stress-induced relapse to alcohol-seeking behavior in rats. Psychopharmacology (Berl). 2000; 150(3):317-24. DOI: 10.1007/s002130000411. View